Accustem Sciences Inc.

Market Cap $3.29M
Debt $57.60K
Cash $37.08K
EV $3.31M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$1.38M
EBIT	-$1.38M
ROA	-1K%
Equity	-$3.19M
Growth Stability	1
PE	-2.39
PB	-1.03
Price/Cash	0.01
Debt/Equity	-0.02
Equity CAGR	-0%
Earnings Growth YoY	-45%
Earnings Growth QoQ	18%
Equity CAGR 5Y	-0%

Equity CAGR 3Y	0%
Market Cap	$3.29M
Assets	$103.82K
Total Debt	$57.60K
Cash	$37.08K
Shares Outstanding	11.35M
EV	3.31M
Working Capital	-3.19M
Current Ratio	0.03
Shares Growth 3y	5%
Equity Growth QoQ	11%
Equity Growth YoY	69%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe.

SEC Filings

Direct access to Accustem Sciences Inc. (ACUT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Accustem Sciences Inc. compare to its competitors?

Not enough data to generate a comparison chart between Accustem Sciences Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Accustem Sciences Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Accustem Sciences Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Accustem Sciences Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-
ROA	-	-399%	-2K%	-1K%
ROE	-	3K%	97%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-
Debt over Equity	-	-0.76	-0.03	-0.02
Growth Stability	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.02)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-
Earnings YoY growth	-	459%	-45%	-
Equity YoY growth	-	-121%	1K%	-0%
FCF YoY growth	-	-	-	-